



**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91-22) 2826 6000  
Fax: (91-22) 2826 7337  
Website: in.pg.com

April 30,2024

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001  
**Ref:- Scrip Code:- 500459**

To,  
The Listing Department  
The National Stock Exchange of India Limited  
Exchange Plaza, Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai – 400051  
**Ref:- Scrip Code:- PGHH**

Dear Sir / Madam,

**Sub:- Unaudited Financial Results for the quarter ended March 31, 2024**

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 12.20 pm and end at 13:07 pm), the Unaudited Financial Results for the quarter ended March 31, 2024 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended March 31, 2024; and
- b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2024 furnished by Statutory Auditors of the Company.

Kindly take the same on record. Thanking you.

For **Procter & Gamble Hygiene and Health Care Limited**

**Flavia Machado**  
**Senior Legal Manager- Legal and Secretarial**



**Procter & Gamble Hygiene and Health Care Limited**  
 CIN : L24239MH1964PLC012971  
 Registered Office: P&G Plaza  
 Cardinal Gracias Road, Chakala  
 Andheri (E), Mumbai 400 099  
 Tel: (91 – 22) 2826 6000  
 Fax: (91 – 22) 2826 7337  
 Website: in.pg.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st MARCH 2024

₹ in Lakhs

Particulars	(1)	(2)	(3)	(4)	(5)	(6)
	Three Months Ended 31st March 2024	Preceding Three Months Ended 31st Dec 2023	Corresponding Three Months Ended 31st March 2023	Nine Months Ended 31st March 2024	Corresponding Nine Months Ended 31st March 2023	Year Ended 30th June 2023
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1 Income</b>						
Sale of products	99 815	1 13 093	88 131	3 26 414	3 05 647	3 90 521
Other operating revenues	402	250	178	981	890	1 269
<b>2 Revenue from operations</b>	<b>1 00 217</b>	<b>1 13 343</b>	<b>88 309</b>	<b>3 27 395</b>	<b>3 06 537</b>	<b>3 91 790</b>
<b>3 Other income</b>	<b>1 359</b>	<b>1 558</b>	<b>1 444</b>	<b>4 494</b>	<b>3 048</b>	<b>4 058</b>
<b>Total income (2+3)</b>	<b>1 01 576</b>	<b>1 14 901</b>	<b>89 753</b>	<b>3 31 889</b>	<b>3 09 585</b>	<b>3 95 848</b>
<b>4 Expenses</b>						
a) Cost of raw and packing materials consumed	16 400	21 457	15 625	59 509	64 765	84 755
b) Purchases of stock-in-trade (Traded goods)	18 086	21 887	21 369	62 258	63 092	82 401
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	( 710)	1 753	1 395	1 617	2 468	( 853)
d) Employee benefits expense	6 009	5 470	4 953	17 851	15 772	20 579
e) Finance costs	2 242	255	357	2 686	838	1 138
f) Depreciation and amortization expense	1 454	1 426	1 458	4 310	4 295	5 836
g) Advertising & sales promotion expenses	13 409	12 670	10 653	41 426	37 298	42 652
h) Other expenses	21 292	19 132	19 387	59 540	57 768	75 393
<b>Total expenses</b>	<b>78 182</b>	<b>84 050</b>	<b>75 197</b>	<b>2 49 197</b>	<b>2 46 296</b>	<b>3 11 901</b>
<b>5 Profit before tax (2+3-4)</b>	<b>23 394</b>	<b>30 851</b>	<b>14 556</b>	<b>82 692</b>	<b>63 289</b>	<b>83 947</b>
<b>6 Tax expense</b>						
a) Current tax	6 967	8 163	4 085	22 663	17 604	23 052
b) Deferred tax	( 820)	( 444)	( 281)	( 1 419)	( 1 294)	( 1 208)
c) Prior year tax adjustments	1 810	242	( 5 750)	2 052	( 5 711)	( 5 711)
	<b>7 957</b>	<b>7 961</b>	<b>( 1 946)</b>	<b>23 296</b>	<b>10 599</b>	<b>16 133</b>
<b>7 Profit for the period (5-6)</b>	<b>15 437</b>	<b>22 890</b>	<b>16 502</b>	<b>59 396</b>	<b>52 690</b>	<b>67 814</b>
<b>8 Other comprehensive income</b>						
Items that will not be reclassified to profit or loss:						
Remeasurement of the defined benefit plans	429	745	503	924	( 10)	( 999)
Income tax effect on above	( 108)	( 188)	( 126)	( 233)	3	251
<b>Total other comprehensive income for the period</b>	<b>321</b>	<b>557</b>	<b>377</b>	<b>691</b>	<b>( 7)</b>	<b>( 748)</b>
<b>9 Total comprehensive income for the period (7+8)</b>	<b>15 758</b>	<b>23 447</b>	<b>16 879</b>	<b>60 087</b>	<b>52 683</b>	<b>67 066</b>
<b>10 Paid-up equity share capital (Face Value ₹ 10 per equity share)</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>	<b>3 246</b>
<b>11 Other Equity</b>						<b>91 357</b>
<b>12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :</b>						
a) Basic	47.56	70.51	50.84	182.98	162.32	208.91
b) Diluted	47.56	70.51	50.84	182.98	162.32	208.91
<b>See accompanying notes to the financial results</b>						

## Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on April 30, 2024 and have been subjected to a limited review by the Statutory Auditors of the Company.  
The Company has arrived at an advanced pricing agreement with the concerned tax authorities, determining appropriate transfer pricing methodology for certain identified transactions with the Company's affiliate(s) for the years viz., F.Y. 2010-11 to F.Y. 2018-19. As a consequence of this agreement, an additional tax liability, amounting to ₹ 1 660 lakhs and interest of ₹ 1 930 lakh, has been accounted under prior period tax adjustments and finance costs respectively. Further, there will be reduction in contingent liability of approximately ₹ 8 699 lakhs, subject to withdrawal of relevant tax litigations by the respective parties.
- During the period ended March 2023 and year ended June 2023, the Company had reversed tax provisions amounting to ₹ 5 844 lakhs in respect of past Income Tax Litigations pertaining to certain years, based on a favourable ruling by the Income Tax Appellate Tribunal in a similar case of the Company pertaining to an earlier year.
- The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.

For and on behalf of the Board of Directors of  
**Procter & Gamble Hygiene and Health Care Limited**

LALGUDI | Digitally signed by  
 LALGUDI  
 VISWANATHAN  
 VISWANATHAN  
 VAIDYANATHAN  
 N  
 VAIDYANATH  
 Date: 2024.04.30  
 12:58:59 +05'30'

**LV Vaidyanathan**  
 Managing Director  
 DIN 09632201

Place: Mumbai  
 Date: April 30, 2024

ROSHNI  
 RAYOMAND  
 MARFATIA

Digitally signed by Roshni Rayomand Marfatia  
 DN: cn=Roshni Rayomand Marfatia, o=Procter & Gamble Hygiene and Health Care Limited, email=Roshni.Rayomand@pg.com, c=IN

**REVIEW REPORT  
TO THE BOARD OF DIRECTORS  
PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED** (“the Company”) for the quarter and nine months ended March 31, 2024, together with the notes thereon, (“the Statement”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, duly initialled by us for identification. This Statement which is the responsibility of the Company’s Management has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on April 30, 2024, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ (‘Ind AS 34’), prescribed under Section 133 of the Companies Act, 2013 (“the Act”) read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For KALYANIWALLA & MISTRY LLP  
CHARTERED ACCOUNTANTS**

Firm Regn. No.: 104607W / W100166

ROSHNI  
RAYOMAND  
MARFATIA

Digitally signed by ROSHNI RAYOMAND MARFATIA  
DN: cn=Roshni, postalCode=400001, st=Maharashtra,  
street=M-42, Curator-Bang-Circle, Mumbai, Mumbai/Maharashtra/India,  
o=ROSHNI - Roshni Electronic House, ou=ROSHNI,  
2.5.4.20=81249d4e4e0e95805c79f91a4e814e0508211090006a8050a  
945048104c  
serialNumber=51883776198541253617363421400366881314896  
604828076246, email=roshni@kalyaniwalla.com, cn=ROSHNI  
RAYOMAND MARFATIA  
Date: 2024.04.30 11:05:09 +0530

*Roshni R Marfatia*

**PARTNER**

M. No.: 106548

UDIN: 24106548BKCSTK1826

Mumbai: April 30, 2024.